Oxford Biomedica (LON:OXB) Sets New 12-Month Low – Here’s What Happened

Oxford Biomedica plc (LON:OXB)’s stock price reached a new 52-week low on Thursday. The stock traded as low as GBX 367.50 and last traded at GBX 569.37, with a volume of 253,422 shares. The stock had previously closed at GBX 552.

Analyst Upgrades and Downgrades

OXB has been the topic of several research reports. Royal Bank Of Canada restated an “outperform” rating and set a GBX 900 price target on shares of Oxford Biomedica in a research report on Tuesday, September 1st. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 595 target price on shares of Oxford Biomedica in a research report on Wednesday, September 2nd. Finally, Jefferies Financial Group reissued a “buy” rating and set a GBX 827 price target on shares of Oxford Biomedica in a research report on Monday, October 26th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Oxford Biomedica presently has a consensus rating of “Moderate Buy” and an average price target of GBX 818.

Oxford Biomedica Price Performance

The firm’s fifty day moving average is GBX 501.69 and its 200 day moving average is GBX 600.07. The company has a market capitalization of £663.17 million, a P/E ratio of -17.08 and a beta of 1.11. The company has a debt-to-equity ratio of 273.08, a quick ratio of 1.67 and a current ratio of 2.21.

Oxford Biomedica (LON:OXB) last issued its earnings results on Wednesday, September 23rd. The biopharmaceutical company reported GBX (30.39) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative net margin of 23.23% and a negative return on equity of 54.51%. As a group, analysts predict that Oxford Biomedica plc will post -31.08 earnings per share for the current fiscal year.

Insider Activity

In other Oxford Biomedica news, insider Roch Doliveux bought 20,250 shares of Oxford Biomedica stock in a transaction on Wednesday, September 23rd. The stock was acquired at an average price of GBX 505 per share, with a total value of £102,262.50. Insiders own 43.30% of the company’s stock.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.